 Esophageal cancer is the 6th most common cause of cancer deaths worldwide and it is an endemic in many parts of the world, particularly in the developing countries, including China. Histologically, esophageal cancer can be classified as adenocarcinoma and esophageal squamous cell. carcinoma ESCC which is the most common histology in Asia. For locally advanced or metastatic ESCC patients, chemotherapy can improve overall survival OS and progression free survival PFS. There is no standard first-line chemotherapy for ESCC patients. Cisplatin DDP plus fluorouracil is the most common used combination with a response rate of 25-35. Previous studies showed that the combination of paclitaxel with cisplatin had good tolerance and efficacy to esophageal carcinoma. This is a prospective randomized control phase III clinical trial to compare the efficacy and safety between docetaxelcisplatin and 5-Fucisplatin as the 1st line treatment in advanced or metastatic esophageal carcinoma patients. 